| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/SYN.21796 |
| P698 | PubMed publication ID | 25522178 |
| P2093 | author name string | I Daniel Limón | |
| Benjamín Florán | |||
| Francisco Paz-Bermúdez | |||
| Brenda González-Hernández | |||
| Ana Báez-Cordero | |||
| Guadalupe Muñoz-Arenas | |||
| René Caballero-Florán | |||
| P2860 | cites work | D2 receptor-mediated inhibition of GABA release by endogenous dopamine in the rat globus pallidus | Q48581395 |
| Histamine H3 receptor activation selectively inhibits dopamine D1 receptor-dependent [3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata | Q48633521 | ||
| Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride | Q48822647 | ||
| Activation of D1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat. | Q48918241 | ||
| Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease | Q48923652 | ||
| Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. | Q48962147 | ||
| Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 | ||
| Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis | Q28268078 | ||
| Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus | Q28573367 | ||
| Adenosine A2A receptor stimulation decreases GAT-1-mediated GABA uptake in the globus pallidus of the rat | Q28580400 | ||
| Localization and function of GABA transporters in the globus pallidus of parkinsonian monkeys | Q30494342 | ||
| Concurrent activation of striatal direct and indirect pathways during action initiation. | Q30579307 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? | Q33211909 | ||
| The fetal hypothalamus has the potential to generate cells with a gonadotropin releasing hormone (GnRH) phenotype | Q33406270 | ||
| Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease | Q33951094 | ||
| Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway | Q34133059 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Pathophysiology of parkinsonism | Q34777496 | ||
| Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats. | Q35014951 | ||
| Role of Striatum in the Pause and Burst Generation in the Globus Pallidus of 6-OHDA-Treated Rats | Q35039660 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Modulation of striatal projection systems by dopamine | Q36367283 | ||
| Past, present, and future of the pathophysiological model of the Basal Ganglia | Q37909948 | ||
| Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 | ||
| Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. | Q41006239 | ||
| The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. | Q42450193 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. | Q42520647 | ||
| Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods | Q42524102 | ||
| Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. | Q43170612 | ||
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
| Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease | Q44237885 | ||
| Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia | Q44451116 | ||
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 | ||
| D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor | Q44666474 | ||
| Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model | Q44933218 | ||
| Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 | ||
| The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. | Q46026291 | ||
| Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when G(i) protein-receptor coupling is restricted: role of dopamine D2 receptors | Q46184685 | ||
| Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 | ||
| GABAergic modulation of the activity of globus pallidus neurons in primates: in vivo analysis of the functions of GABA receptors and GABA transporters | Q46437070 | ||
| 6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat. | Q46511780 | ||
| The CB1 cannabinoid receptor in the brain. | Q48285234 | ||
| Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease | Q48435185 | ||
| P433 | issue | 3 | |
| P921 | main subject | CNR2 | Q17907844 |
| cannabinoid receptor | Q421237 | ||
| cannabinoids | Q422936 | ||
| P304 | page(s) | 103-114 | |
| P577 | publication date | 2014-12-23 | |
| P1433 | published in | Synapse | Q7662025 |
| P1476 | title | Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry | |
| P478 | volume | 69 |
| Q92295837 | GPRIN3 Controls Neuronal Excitability, Morphology, and Striatal-Dependent Behaviors in the Indirect Pathway of the Striatum |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q50422457 | The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra |
Search more.